Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia
about
Tissue factor and its natural inhibitor in pre-eclampsia and SGAAngiotensin receptors, autoimmunity, and preeclampsiaAngiogenic factors in preeclampsia: potential for diagnosis and treatmentAn unexpected tail of VEGF and PlGF in pre-eclampsiaVascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseasesInnate immunity, decidual cells, and preeclampsiaControl of human trophoblast functionNovel biomarkers for predicting preeclampsiaAcute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus.Molecular mechanisms of preeclampsia.Fully Bayesian tests of neutrality using genealogical summary statistics.Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia.Abnormalities in oxygen sensing define early and late onset preeclampsia as distinct pathologies.The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.Vascular and cellular calcium in normal and hypertensive pregnancyB cells: the old new players in reproductive immunology.Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.Therapeutic potential of manipulating VEGF splice isoforms in oncologyBeyond oxygen: complex regulation and activity of hypoxia inducible factors in pregnancy.Maternal plasma soluble TRAIL is decreased in preeclampsia.Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1.Angiogenesis and chronic kidney disease.Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.Comparison of thyroid hormone levels between normal and preeclamptic pregnancies.Choroidal and retinal thickening in severe preeclampsia.Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaaPregnancy-induced hypertension and preeclampsia: levels of angiogenic factors in malaysian womenUnexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluidAn imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study.In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy.Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia.Pro-inflammatory profile of preeclamptic placental mesenchymal stromal cells: new insights into the etiopathogenesis of preeclampsia.Circulating angiogenic and antiangiogenic factors in women with eclampsia.Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer.Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes.Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis.Glyceryl trinitrate inhibits hypoxia-induced release of soluble fms-like tyrosine kinase-1 and endoglin from placental tissuesPreeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia.
P2860
Q24323351-8E21A090-0DE4-4660-9EC7-C300E8F7B179Q24605647-C822512A-1125-4641-A941-1B8C4075B43CQ26825774-3B52A998-5441-43C0-BC88-A8BE2C78E03FQ27000996-D14D7C7D-29D5-4E73-923E-7C998F27DBBFQ27004077-565C9319-85F0-452D-A1C8-CC8A98738FC4Q27014127-9BE128DD-F105-4E17-8CD5-3AE2A9F3B60FQ28218814-6BEA369E-9491-41AD-8B76-7F08B2552AEDQ28386182-C24D83F1-40C9-48C4-A793-502C82514B2BQ31074551-F0377082-0170-468B-A385-E5430CA1D009Q33344105-8DC04ABC-50F5-4AFB-A1AB-598D788167CDQ33352330-EAF0AC01-20D2-498F-8737-DC1EAA752D7DQ33438425-84BC6ECF-6BD8-442E-9D09-483A401EA80AQ33725645-DB77FBC2-7C33-4D11-9FE6-D9516DD3FBF0Q33755648-8BA8CD98-E850-43A8-AC1C-2557696D1643Q33781354-9E6FECB8-2188-4C24-83D0-0FF3588C3F39Q33789436-5CBC5449-E01F-42C3-9647-0F5E31BF5243Q33863973-AF615B71-D40F-442F-A534-49EB97AACFF6Q33888458-1C721A33-BCC3-4A05-97E8-E22359F6F7B3Q33894600-41458911-3388-4285-B382-A1BFF041B3BEQ33909572-6955A7B6-FD73-48D0-BA9D-72A70C4AF41AQ34073285-36BBB930-5D98-464D-8F08-451AA3005A1EQ34075013-531B25B8-71BB-4E84-9B12-2460005E12F6Q34119026-53B9969C-801E-4A98-92C4-53121FA66D73Q34131850-254D9779-3649-4EEA-AF87-3A8C308BB824Q34166713-28633766-4E0B-484D-B08D-538B70C1412CQ34182374-851AF618-4A4B-4304-9289-72B08CD515B8Q34255236-A48C7E57-BD85-49C3-8B74-625B65EE39C6Q34470845-679C28BF-778B-4337-9FDD-7A321E7AFDEDQ34505090-E8BB111A-3978-4715-B571-C2BB889CBDD1Q34505704-9157115D-D909-4792-925F-E8E3A8DCC048Q34619975-D73EE843-8CB2-4B26-9BD5-092FE740996BQ34635145-8AC77042-569D-43F1-8ED1-D517D221FEB3Q34670638-8579457F-5EB7-4D74-A956-95C047C9DA6DQ34706749-D5F7AA2B-60A9-4FE0-85F0-29907D411182Q34972727-A60BAA95-A42F-48D9-9EA8-0B3A7FA7A447Q35015402-7369B11C-95D4-4065-A6AD-93233A3CE6A4Q35047445-3008A543-5272-419E-8278-1D07FF80D9B4Q35070633-9303C645-58F8-4D89-8945-1F26FF4A3625Q35143007-B6294977-3436-417C-B49A-E0F7FAC9F187Q35145097-B7C9EB90-C184-4DAA-8066-6735F33E8FA0
P2860
Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia
description
im Mai 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 May 2003
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2003
@uk
name
Elevated Serum Soluble Vascula ...... els in Women with Preeclampsia
@en
Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1
@nl
type
label
Elevated Serum Soluble Vascula ...... els in Women with Preeclampsia
@en
Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1
@nl
prefLabel
Elevated Serum Soluble Vascula ...... els in Women with Preeclampsia
@en
Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1
@nl
P2093
P356
P1476
Elevated serum soluble vascula ...... els in women with preeclampsia
@en
P2093
Kaori Koga
Osamu Tsutsumi
Osamu Yoshino
Tetsu Yano
Tetsuya Hirata
Xie Ruimeng
Yuji Taketani
Yutaka Osuga
P304
P356
10.1210/JC.2002-021942
P407
P577
2003-05-01T00:00:00Z